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Abstract 
The majority of diagnostic decisions are made on results from blood-based tests, and 
protein measurements are prominent among them. However, current assays are 
restricted to individual proteins, whereas it would be much more desirable to measure 
all of them in an unbiased, hypothesis-free manner. Therefore, characterization of the 
plasma proteome by mass spectrometry holds great promise for clinical application. 
Due to great technological challenges and study design issues, plasma proteomics has 
not yet lived up to its promises: no new biomarkers have been discovered, plasma 
proteomics has not entered clinical diagnostics and few biologically meaningful insights 
have been gained. As a consequence, relatively few groups still continue to pursue 
plasma proteomics, despite the undiminished clinical need. 
The overall aim of my PhD thesis was to pave the way for biomarker discovery and 
clinical applications of proteomics by precision characterization of the human blood 
plasma proteome. First, we streamlined the standard, time consuming and labor-
intensive proteomic workflow, and replaced it by a rapid, robust and highly reproducible 
robotic platform. After optimization of digestion conditions, peptide clean-up procedures 
and LC-MS/MS procedures, we can now prepare 96 samples in a fully-automated way 
within 3h and we routinely measure hundreds of plasma proteomes. Our workflow 
decreases hands-on time and opens the field for a new concept in biomarker discovery, 
which we termed ‘Plasma Proteome Profiling’. 
It enables the highly reproducibility (CV<20% for most proteins), and quantitative 
analysis of several hundred proteins from 1 µl of plasma, reflecting an individual’s 
physiology. The quantified proteins include inflammatory markers, proteins belonging to 
the lipid homeostasis system, gender-related proteins, sample quality markers and more 
than 50 FDA-approved biomarkers. One of my major goals was to demonstrate that MS-
based proteomics can be applied to large cohorts and that it is possible to gain 
biologically and medically relevant information from this. We achieved this aim with our 
first large scale plasma proteomic study in which we analyzed by far the largest plasma 
proteomics study with almost 1,300 proteomes, which allowed us to define inflammatory 
and insulin resistance panels in a weight loss cohort. 
In summary, this PhD thesis has developed the concept and practice of Plasma 
Proteome Profiling as a fundamentally new approach in biomarker research and medical 
diagnostics – the system-wide phenotyping of humans in health and disease.  
 
Abstract 
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Zusammenfassung 
Der Großteil aller diagnostischen Entscheidungen basiert auf Bluttests, wobei Proteine 
den größten Anteil der untersuchten Analyten einnehmen. Die klinisch eingesetzten 
Assays sind jedoch auf einzelne Proteine beschränkt und es wäre erstrebenswert 
möglichst alle Proteine in einer einzelnen Messung hypothesenfrei und objektiv zu 
erfassen. Deshalb wäre die massenspektrometrische Charakterisierung des Plasma 
Proteomes ein sehr vielversprechender Ansatz. 
Große technologische Herausforderungen und schlecht konzipierte Studien führten 
jedoch dazu, dass die Massenspektrometrie (MS)-basierende Proteomics die hohen 
Erwartungen bis heute nicht erfüllen konnte: kein einziger neuer Biomarker wurde 
mittels Proteomics entdeckt, die Massenspektrometrie hat nicht den Sprung in die 
klinische Anwendung geschafft und es war nicht möglich bedeutende biologische 
Erkenntnisse aus dem Plasma zu gewinnen. Dies führte dazu, dass heute nur noch 
relativ wenige Forschungsgruppen das Plasma Proteom untersuchen, obwohl der 
medizinische Bedarf noch immer genauso groß ist. 
Das Ziel meiner Doktorarbeit war es den Weg für die Entdeckung neuer Biomarker und 
der klinischen Anwendung von Proteomics zu ebnen. Der typische Arbeitsablauf in der 
Proteomics ist sehr zeitintensiv und aufwendig. Deshalb haben wir ihn zuerst 
grundlegend vereinfacht und auf Schnelligkeit, Robustheit und Reproduzierbarkeit 
optimiert. Nach der Verbesserung von Verdaubedingungen, der Peptid-Aufreinigung 
und der Instrumentenparameter sind wir nun in der Lage 96 Proben vollautomatisiert 
innerhalb von 3 Stunden vorzubereiten und hunderte von Plasma Proteomen am Stück 
zu messen. Dieser Arbeitsablauf vereinfacht nicht nur die proteomische Anwendung im 
Allgemeinen, sondern eröffnet auch die Möglichkeit eines neuen Konzepts in der 
Biomarkerforschung. 
Dieses neue Konzept bezeichnen wir als „Plasma Proteome Profiling“. Es erlaubt die 
hochreproduzierbare (CV<20%) Quantifizierung von hunderten von Proteinen aus 
einem Mikroliter Plasma und liefert damit eine Reflektion des Gesamtzustandes eines 
Menschen. Unter andern messen wir Entzündungsmarker, Proteine des 
Fettstoffwechselsystems, geschlechts-spezifische Proteine, Qualitätsmarker und 
zudem über 50 verschiedene bereits klinisch angewendete Biomarker. Eines meiner 
zentralen Ziele war es die Messung großer Kohorten zu ermöglichen. So haben wir die 
bis heute größte Plasma Proteomics Studie mit annähernd 1300 Plasma Proteomen 
analysiert und dabei klinisch bedeutende Informationen über den Entzündungsstatus 
und die Insulin-Resistenz-Neigung von Studienteilnehmern entdeckt. 
                   Abstract 
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Das in dieser Doktorarbeit entwickelte Konzept von Plasma Proteom Profiling ist ein 
grundsätzlich neuer Ansatz in der Biomarkerforschung und auch für die medizinische 
Diagnostik, die zum Phänotypisieren von Menschen mittels minimaler Blutmengen 
eingesetzt werden kann. Bereits heute setzen wir Plasma Proteomics Profiling auf 
täglicher Basis zur Erforschung neuer krankheitsrelevanter Biomarker in verschiedenen 
Studien ein. Auch weiterhin investieren wir viel Energie in die Erforschung neuer 
Technologien um unsere Idee der proteomischen Phänotypisierung mittels Plasma 
Proteom Profiling noch weiter auszubauen und sie schließlich in die klinische 
Anwendung zu übertragen.  
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1. Introduction 
 
1.1. Mass spectrometry-based exploration of the proteome 
Proteins control and execute the vast majority of biological processes. Changes in their 
expression levels, activity, localization or interaction characterize different states of 
biological systems. The proteome is defined as the entirety of all proteins in a biological 
system and proteomics is the technology and approach for its large-scale investigation. 
The proteomics field has benefited from continuous development over the last 20 years. 
Starting from gel electrophoresis-based to high technology mass spectrometry (MS)-
based methods, proteomics now allows the holistic investigation of diverse biological 
conditions and processes (Aebersold and Mann, 2016; Larance and Lamond, 2015).  
The initial breakthrough for MS-based proteomics was the development of soft ionization 
techniques for large molecules in the late 1980s. Especially two technologies allowed 
the ionization and vaporization of proteins and peptides: Matrix-assisted laser 
desorption/ionization (MALDI) and electrospray ionization (ES) (Fenn et al., 1989; Karas 
et al., 1985; Tanaka, 1988). ES became especially popular in research because it can 
be easily coupled with a liquid chromatography system (LC). In ES, the analytes are 
volatized and ionized directly out of a solution by dispersion of the liquid into very small, 
charged droplets that rapidly evaporated, transferring charges to desolvated, labile 
analytes (Kebarle and Tang, 1993). John Fenn was awarded a share of the chemistry 
Nobel Prize for his invention of electrospray ionization for large molecules in 2002. 
Further technological breakthroughs were the combination of peptide sequence tag 
algorithms for the identification of peptides in DNA databases and the development of 
highly sensitive nanoelectrospray (Mann and Wilm, 1994; Wilm and Mann, 1996).  
In principle, purified intact proteins can directly be analyzed by MS-based proteomics, a 
technology called ‘top-down’ proteomics (Catherman et al., 2014). However, ions with 
lower mass are more sensitive in MS-based analysis and intact protein measurements 
are not as informative, which has meant that top-down proteomics is confined to special 
niches such as protein drug characterization. In contrast ‘bottom-up’ proteomics has 
been broadly successful and is the mainstay of MS-based proteomics today. For a long 
time and still today proteins have been analyzed by polyacrylamide gels but it was not 
possible to continue from gels to MS analysis. The development of ‘in-gel digestion’ 
protocols enabled the efficient isolation of peptides from polyacrylamide gels and high 
sensitivity analysis of biological systems (Saccharomyces cerevisiae) (Shevchenko et 
al., 2006; Shevchenko et al., 1996). Combined with nanoelectrospray and peptide 
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sequence tags, this for the first time made mass spectrometry applicable to low level 
analysis of important proteins and MS has been the method of choice for their analysis 
ever since (Mann, 2016; Wilm et al., 1996). 
 
 
 
Figure 1: Shotgun proteomics workflow. (A) In the sample preparation step, proteins are extracted from 
cells or tissue and enzymatically digested to peptides. Fractionation can be applied at the protein or peptide 
levels to increase proteome coverage. (B) Peptides are separated by a high-performance liquid 
chromatography (HPLC) system and ionized by electrospray for subsequent mass spectrometry (MS) 
analysis. The typical schema of a data dependent top N method for data acquisition is depicted (one MS1 
scan followed by n MS2 scans). (C) Bioinformatic spectra interpretation uses the information from the full 
MS (MS1) and MS2 spectra for data searching. From (Hein et al., 2013). 
 
Over the years, sample preparation has remained a key component of proteomics 
(Figure 1 A). The aim of a typical sample preparation workflow is to harvest proteolytic 
peptides suitable for bottom-up MS. The process usually starts with the lysis of cells or 
tissue, followed by the reduction of intra- and inter-protein disulfide bonds. Alkylation is 
necessary in order to prevent the reactive thiol groups of cysteine residues from forming 
disulfide bridges again. The next step in generating peptides is digestion by sequence 
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specific enzymes. These generate predictable terminal amino acids, supplying further 
constraints for bioinformatics peptide identification. Trypsin and/or LysC are almost 
always used because they generate particularly favorable peptides for MS 
fragmentation and identification.  
Past protocols often used strong detergents like sodium-dodecyl-sulfate (SDS) for cell 
lysis, which also results in the denaturation of the digestion enzymes and is in any case 
incompatible with ES. Protocols have been developed to remove the detergents e.g. by 
protein precipitation or ‘Filter-Aided Sample Preparation’ (FASP) (Wisniewski et al., 
2009). However, apart from recurrent issues regarding reproducibility, these multi-step 
protocols frequently suffered from remaining detergent contamination, negatively 
affecting digestion efficiency. In 2014, Kulak et al. published the ‘in-StageTip’ digestion 
protocol, an all-in-one reaction buffer system for cell lysis, reduction and alkylation of 
cysteine residues and highly efficient digestion on the solid-phase extraction matrix 
(Kulak et al., 2014). Solid phase extraction then delivers clean peptides, ready for MS 
analysis. This protocol not only radically increased digestion efficiency but also virtually 
eliminated hands on time. 
In the next step of the proteomic workflow, peptides are separated according to 
hydrophobic interactions with initially a mobile and later a stationary phase in a high-
pressure liquid chromatography (HPLC) system (Figure 1 B). Peptides elute from the 
column in a sequential manner and are immediately ionized in the electrospray source. 
HPLC systems operating in the nano-flow range have proven to be especially efficient 
for peptide separation and the following ionization, resulting in high sensitivity.  
Today’s mass spectrometers are highly complex systems. They consist of a large 
number of components that focus the ion beam with lenses in the vacuum, effect the 
ions flight path by dynamic electric fields, allow to filter for ions with distinct mass to 
charge (m/z) ratios and break them into smaller fragments at selectable energies. The 
fact that an ion behavior in the vacuum is strictly dependent on its m/z can be used for 
identification and quantification. Many types of mass analyzers and detectors are used 
for this purpose. 
A typical MS-measurement uses two steps (MS1 and MS2) to acquire the necessary 
information for peptide identification. In the MS1 step (full scan), a broad-range mass 
spectrum (e.g. m/z=300-1,650 Th) is acquired, delivering m/z values for all intact peptide 
masses at a distinct time point during the LC run. In the MS2 scan a single ion species 
is selected and fragmented according to an intensity-based priority list (top N method) 
and the fragments masses are determined. The MS1 and MS2 measurements deliver 
1. Introduction 
4 
the data that is used in the identification of the peptides (Figure 1 C). As peptides are 
combinations of amino acids with distinct masses it is in principle possible to determine 
their sequences. The MS1 spectrum provides the intact peptide mass and thus 
constrains the peptide’s amino acid composition. For all peptide sequences in the 
database with a compatible mass that satisfies the enzyme specificity, the MS2 spectra 
are calculated. The number of matches to the measured fragments is converted to a 
score that reflects the likelihood that these matches occurred by chance. False 
Discovery Rates (FDRs) are then rigorously determined by comparison to the number 
of peptide and protein matches in a sequence reversed database. In this thesis, peptide 
and protein identification and quantification were all performed in the MaxQuant suite of 
computational tools (Cox and Mann, 2008; Tyanova, 2016).  
The last years have seen dramatic improvements in all areas of the MS-based 
proteomics workflow, ranging from sample preparation to measurement and subsequent 
bioinformatic analysis (Aebersold and Mann, 2016; Bantscheff et al., 2012; Cox and 
Mann, 2011; Munoz and Heck, 2014). Together, these advances have enabled the 
broad application of quantitative proteomics in biological research, resulting in 
thousands of publications each year. Today, specialized proteomic laboratories identify 
quasi-complete proteomes of more than 10,000 proteins in mammalian model 
organisms (Bekker-Jensen et al., 2017; Geiger et al., 2012; Kulak et al., 2017; Richards 
et al., 2015) and apply their workflows to a diverse array of cell biological, biochemical 
and medical processes (Figure 2). This has also answered basic questions relating to 
the regulation of the proteome, including mRNA translation efficiency – in this case 
showing a highly protein specific regulation (Lahtvee et al., 2017; Nagaraj et al., 2011). 
Moreover, temporal regulation of protein expression and modification during the cell 
cycle (Ly et al., 2014; Olsen et al., 2010) and spatial distribution of proteins with 
subcellular organelle maps haven been used to investigate protein dynamics on a global 
scale (Andersen et al., 2005; Itzhak et al., 2016). Interaction partners of a protein of 
interest can be revealed by ‘pull-down’ experiments. The global application of this 
technology resulted in drafts of the human interactome, an extensive network analysis 
of the connections of thousands of proteins (Hein et al., 2015; Huttlin et al., 2017). Even 
symbiotic association can be disentangled at the proteome level, such as the one 
between legumes and nitrogen-fixing bacteria (Marx et al., 2016). Finally, the analysis 
of signaling pathways by enrichment of phosphorylated peptides allows researchers to 
uncover complex signal transduction pathways in vitro and in vivo (Humphrey et al., 
2015).  
          1. Introduction 
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The integration of several types of human tissue proteomes combined with data 
generated by the community resulted in two first ‘drafts of the human proteome’ (Kim et 
al., 2014; Wilhelm et al., 2014). Although these maps were by no means complete and 
their analysis methods are controversial, they illustrate the desire to determine the 
complete proteome as are a first step towards an understanding of the complex protein 
composition in the human body. More focused projects revealed cell type and region 
specific maps of whole mammalian organs, providing insights into biological processes 
in model animals and humans (Aye et al., 2010; Azimifar et al., 2014; Sharma et al., 
2015). 
 
 
Figure 2: Proteomics exploration of a cell. Proteins in their various forms and modifications can be 
investigated by different proteomics techniques to explain diverse cellular processes on the molecular level. 
From (Hein et al., 2013). 
 
1.2. Clinical proteomics 
Precision medicine is a key aim of modern medical science, directly connected to 
individualized treatment and disease prevention (Collins and Varmus, 2015). It is driven 
by the idea that inter-individual biological variances determines the differences in 
disease presentation and subsequent response to treatment. Large scale technologies 
that have the power to differentiate between individuals such as genomics, 
transcriptomics and proteomics all have the promise to personalize medicine. The 
proteome is the most direct molecular representation of the phenotype, levels of 
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individual proteins are already widely applied as indicators of diseases in clinical practice 
and most drugs influence the activities or concentrations of proteins. Therefore, 
proteomics should in principle be an ideal technology to investigate disease 
mechanisms. Clinical proteomics could be used in a multi-faceted manner to deliver on 
the promises of personalized medicine: diagnosing diseases in early stages, correlating 
protein patterns for disease sub-classification, predicting disease progression and 
finding causal molecular targets for new treatment strategies.  
Research groups around the globe strive to address the diverse medical needs of 
society. Some clinical questions can be readily answered using cell line systems. In this 
context, proteomics has been successfully applied to disentangle the respective 
mechanisms of actions of drug treatments, see for example (Sacco et al., 2016), and it 
has also been used to find off-target effects of therapeutics (Bantscheff et al., 2007; 
Klaeger et al., 2016). Only a minority of diseases have obvious causal mechanisms such 
as monogenetic disorders; rather pathogenicity usually depends on the accumulation of 
multiple diverse epigenetic and environmental factors. Even in cancer, where the 
underlying defect is gene mutation, there is complexity in the cumulative tumor 
heterogeneity. Cells within a single tumor can exhibit diverse mutations due to clonal 
evolution. Further heterogeneity comes from the immediate microenvironment level 
(blood vessels, interaction with stroma, nutrients), while there is a nearly infinite 
variability at the level of the host that may influence tumor progression (immune 
response, microbial response, age of host, environment exposure). Thus model 
organisms can only help in providing a generalized, simplified overview. Investigation of 
diseased tissues or body fluids of individuals can shed light on protein-based molecular 
mechanisms and proteomics has already been successfully applied to the investigation 
of tumor samples. Disease specific patterns have been identified and further sub-
stratification of individuals within one disease has been achieved, see for example 
(Deeb et al., 2015; Mertins et al., 2016; Tyanova et al., 2016; Zhang et al., 2014).  
Tissues are generally only available for diseases where surgery is a necessary 
treatment step. In other cases, they have to be obtained post mortem. In contrast, body 
fluids like saliva, urine, stool and tears are sampled non-invasively or in the case of blood 
by minimally invasive procedures. Evidently, they represent a unique opportunity in 
terms of potential clinical utility and research potential. As a consequence, there are 
clinically established tests for all of them. Blood and blood derived matrices like plasma 
and serum (collectively referred to a ‘plasma in this thesis) are by far the most important 
ones for diagnostic purposes and will be discussed separately below.  
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In the past decades, the proteomics field has collectively endeavored to search for new 
biomarkers in body fluid proteomes. For instance, in stool samples chemical and 
immunological tests are used to detect blood in the context of colorectal cancer 
screening (Rex et al., 2009). Stool mainly consists of bacteria and this has become the 
focus of much current research. The microbiome has been investigated in a wide range 
of conditions and diseases by next-generation sequencing (NGS) methods and these 
analyses clearly reveal the profound influence of the microbiome in many diseases 
(Lynch and Pedersen, 2016). A recent proteomic study in human and mice achieved 
high proteome coverage of more than 30,000 microbial and host proteins in mice and 
19,000 in humans (Zhang et al., 2016). In our group we investigated the microbial 
community of human saliva by proteomics, quantifying 5,500 human and 2,000 microbial 
proteins. We found drastic remodeling of the microbiome in response to food intake and 
tooth brushing (Grassl et al., 2016). In the clinic, saliva samples are routinely tested for 
a broad range of diseases like HIV or helicobacter pylori (Malamud, 2011). A broad 
range of analytes, especially small molecules, are determined in urine, but total protein 
levels are also tested to detect increased glomerulus permeability e.g. in infectious 
diseases, diabetes, hypertension and general kidney malfunction. Human chorionic 
gonadotropin (hCG) is the commonly detected substance in pregnancy tests, which is 
also performed in urine. The proteomic community has investigated the urine proteome 
extensively, achieving a depth of nearly 3,500 proteins (Santucci et al., 2015). Tear fluid 
is also interesting for diagnosis and proteomic studies report more than 1,500 identified 
proteins (Aass et al., 2015).  
In the past and present, plasma forms the basis of standard clinical diagnosis and this 
will in all likelihood continue in the future. In the realm of proteomics, plasma has also 
emerged as a center of attention. This fact is clearly reflected in a comparison of the 
collective number of publications regarding urine, stool, saliva and tears vs. those that 
investigate either blood, plasma and serum. As of May 2017 this ratio stands at 1,500 
to 7,700. In light of this, it is unfortunate that, due to a variety of technical and conceptual 
shortcomings, the exploration of the human plasma proteome has proven to be 
somewhat of a disappointment, with essentially no proteomics-derived biomarker having 
been integrated into clinical practice.  
 
1.3. The blood plasma proteome 
Blood is considered the foremost bodily fluid and around 5 L are circulating in the human 
body. It serves as the medium through which a vast array of functions is executed: 
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oxygen and nutrients are provided, metabolites are carried and removed, signaling 
molecules are transported for inter-organ communication, body temperature is regulated 
and pathogens are fought by the immune system.  
Blood is a suspension, consisting of a cellular (~40%) and a liquid component (~60%) 
(Fischbach, 2009). Its cellular portion can be classified into erythrocytes, thrombocytes 
and leucocytes. Erythrocytes are the most abundant ones (~5*106 cells/µL), responsible 
for the transport of oxygen and for pH buffering. Thrombocytes (~1-4*105 cells/µL) are 
the protagonists of haemostasis, initiating repair upon injuries. Leucocytes (5-10*103 
cells/µL) constitute a broad class of immune cells of which granulocytes and monocytes 
are responsible for the unspecific and lymphocytes (B cells, T cells, NK cells) for the 
specific immune response. 
The straw-coloured liquid portion of blood is called plasma, in which all components are 
retained whereas serum remains after activation of the coagulation cascade. In our 
experience, serum and plasma are equally suited to proteomic analysis.  
 
 
Figure 3: Functional annotation of the plasma proteome. (A) Plasma proteins are spread over a 
dynamic range of at least ten orders of magnitude. Typical serum proteins are annotated in the abundance 
plot. The three boxes reflect classification into functional, tissue leakage and signal proteins according to 
the proteins and their keyword annotation from Anderson (Anderson and Anderson, 2002). (B) Keyword 
annotation and one-dimensional enrichment analysis provide a functional reflection of the plasma proteome 
based on bioinformatic analysis (Cox and Mann, 2012). Protein concentrations were derived from the 
Plasma Proteome Database (Nanjappa et al., 2014). Adapted from (Geyer et al., 2017). 
 
The plasma proteome – the entirety of all proteins present in plasma – can be 
categorized into three general classes based on functionality (Anderson and Anderson, 
2002; Surinova et al., 2011): highly abundant proteins with specific roles in plasma, 
medium abundant tissue leakage proteins with no dedicated purpose in plasma, and low 
abundant signalling proteins (Figure 3 A). The concentration difference between the 
most abundant protein serum albumin (ALB) at around 50 mg/mL and the lowest 
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concentrated cytokines e.g. interleukin 1 beta (IL-1β) with less than 5 pg/mL, results in 
a dynamic range spanning more than ten orders of magnitude. Note that the 
categorization into abundance and functional classes is only approximate; for instance, 
there are very low abundance tissue leakage proteins with no functional role. 
In the high abundant class, albumin maintains the osmotic pressure, the apolipoprotein 
family transports insoluble molecules such as lipids, haptoglobin sequesters free 
haemoglobin that would otherwise harm the kidneys, serotransferrin recycles free iron, 
acute phase proteins defend the body against pathogens and the proteins of the 
coagulation cascade initiate wound healing. Tissue leakage proteins may be released 
by shedding into the circulation such as the apolipoprotein receptors SRB1, LRP1 and 
LDLR from the liver or by tissue damage like prostate specific antigen (PSA) (Vihko et 
al., 1978), which is elevated in prostate cancer patients. Likewise, increased levels of 
the cardiac muscle troponin T (TNNT2) may indicate a myocardial infarction (Hamm et 
al., 1992). The third class consists of messenger molecules like small protein or peptide 
hormones (e.g. insulin or ghrelin) and cytokines, which typically have very low 
abundances at steady state and are upregulated on demand.  
The diverse functions of the plasma proteome, distributed over the entire concentration 
range, are displayed in figure 3 B. Keyword annotations of a list of 1,176 proteins and a 
subsequent ‘one-dimensional enrichment analysis’ (Cox and Mann, 2012) identified 67 
significantly enriched terms. These cover only keywords that are connected to multiple 
proteins and thus even underestimate the functional complexity of the plasma proteome. 
For example, copper transport is executed by a single protein (ceruloplasmin), whose 
function is not enriched in such an analysis. 
 
1.4. Biomarkers and the clinical plasma proteome 
According to the US National Institutes of Health (NIH) Biomarkers Definitions Working 
Group, a biomarker is a defined characteristic that can be quantified as an indicator of 
a normal biological process, pathogenic process, or a response to an exposure or 
intervention (Biomarkers Definitions Working, 2001). The BEST resource (FDA-
NIH:Biomarker-Working-Group, 2016) of the American Food and Drug Administration 
(FDA) classifies biomarkers into seven categories (Figure 4 A). 
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Figure 4: Biomarkers and their clinical application. (A) Biomarkers are divided by the FDA into the seven 
indicated categories according to the BEST resource (2016). (B) Proportion of clinical decisions that are 
made based on laboratory testing. (C) Proportion of clinical tests that are based on different molecule types. 
Adapted from (Geyer et al., 2017). 
 
Biomarkers have a profound role in clinical decision making. According to a survey of 
our collaborators at the Institute of Laboratory Medicine at the Klinikum Großhadern – 
one of the largest University Hospitals in Germany – 77% of all clinical decisions are 
based on laboratory tests (Figure 4 B) (Geyer et al., 2017). The largest group of these 
(42%) measures the concentrations or enzymatic activities of proteins (Figure 4 C). In 
daily clinical practice, the quantitative analysis of individual plasma proteins is 
overwhelmingly performed with immuno- or enzymatic-assays that target single 
proteins. This is because these tests have inherent limitations regarding multiplexing 
and antigen-antibody recognition. Such limitations include cross-reactivity, non-linear 
responses (Hook effect) and interference by background molecules such as triglycerides 
(Hoofnagle and Wener, 2009; Wild, 2013). Furthermore, there are a plethora of clinically 
important protein variants that are difficult to detect by antibody-based assays. One 
example is apolipoprotein(a), a marker for the assessment of cardiovascular disease 
risk (Danesh et al., 2000). Apolipoprotein(a) contains a number of kringle IV domains 
that is genetically determined. These affect the structure of the protein and the affinity 
of the antibody towards it (McConnell et al., 2014). Another example is vitamin D binding 
protein of which there are three common isoforms in humans, each reacting differently 
in clinical immunoassays. A frequent polymorphism in African Americans has resulted 
in the underestimation of vitamin D binding protein levels and in the mistaken notion that 
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African Americans have lower concentrations of this proteins in general (Powe et al., 
2013).  
To date, the concept of protein biomarker discovery and measurement is generally 
synonymous with single protein tests, with the unstated implication that there should be 
a biomarker for each disease. However, this notion suffers from an inherent conceptual 
limitation: there are only about 20,000 human genes and the number of different human 
diseases is nearly as large – 14,400 according to the International Classification of 
Diseases (ICD). Biologically, it appears unlikely that a distinct protein-based biomarker 
exists for each and every disease (and it would already be arithmetically impossible). 
Even adding non-protein compounds such as metabolites, would not change the 
situation appreciably. A more promising concept would be to combine proteins into 
‘multi-biomarker panels’. This generates a very large number of degrees of freedom – 
many more than the number of different disease. Even a small panel consisting of five 
arbitrary proteins with binary states would result in about 20,0005 = 3*1021 possible 
combinations. Apart from potentially enabling many more potential patterns than single 
protein assays, multi-biomarker panels could also more readily account for inter-
individual variability. For example, one of the studies described in this thesis defines a 
multi-protein inflammation panel consisting of 10 proteins that reflects low level 
inflammation in the body (Geyer et al., 2016a). Interestingly, in clinical practice there are 
some examples of multi parameter diagnostic scores like the sFlt-1/PIGF ratio for the 
diagnosis of preeclampsia (Levine et al, 2004) or the integration of albumin, bilirubin, 
quick test, ascites and encephalopathy into the Child-Pugh-score for liver cirrhosis 
(Pugh et al., 1973). 
Currently, there are only about 100 FDA cleared or approved clinical plasma or serum 
tests available. Furthermore, more than 80% of these have been implemented more 
than 20 years ago. In the past two decades, the rate of discovery of new biomarkers has 
remained constant or even declined, with less than two new biomarkers incorporated 
into clinical practice per year (Anderson, 2010; Geyer et al., 2017).  
Given the fundamental limitations of individual protein assays, MS-based methods are 
in principle an attractive alternative for clinical applications as well as biomarker research 
as they are inherently capable of discovering multi-protein panels. However, the 
technological challenges are daunting and call for drastic improvements in robustness, 
sensitivity and throughput compared to what is available at the moment.  
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1.4.1. Challenges of plasma proteomics 
 
1.4.1.1. Pitfalls of the past 
Given the attractiveness of plasma proteomics, many research groups around the globe 
have attempted to mine the human plasma proteome in search of new biomarkers over 
the last decades. Unfortunately, despite these individual efforts and those of the Human 
Proteome Organization’s Plasma Proteome Project (Omenn et al., 2005), this major goal 
of our community has not fulfilled its initial promises. In retrospect, this is clearly due to 
several intractable technological challenges, which were not sufficiently addressed at 
the time.  
On the biomarker side, the only case in which plasma proteomics was partially 
successful was the OVA1 test (Rai et al., 2002; Zhang et al., 2004). OVA1 consists of a 
five protein panel used to distinguish between benign and malignant ovarian tumors in 
very specific indications. Four of the proteins are the highly abundant plasma proteins 
beta-2 macroglobulin, apolipoprotein A1, serotransferrin and pre-albumin. They were 
identified by proteomics but are very unlikely to be specific to ovarian cancer status. 
Their levels are combined with the already known biomarker CA125 and the patient´s 
menopausal status into a risk score.  
 
 
Figure 5: Literature review of plasma proteomics. The total number of publications using MS-based 
proteomics are more than 10-times higher than the plasma proteomics literature (search terms: [proteomics 
AND mass spectrometry]; [plasma AND proteomics AND mass spectrometry]). The low level and 
fluctuations in the number of publications per year for plasma proteomic are in stark contrast to the steadily 
increase in MS-based proteomic publications in general. 
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In reviewing the history of plasma proteomics, we found that there have been two 
periods of particular activity towards the discovery of new biomarkers. This is reflected 
in spikes of publication numbers in plasma proteomics compared to the total number of 
publications in the field of proteomics (Figure 5). Disregarding an initial phase in which 
two dimensional gel electrophoresis was employed, the first period started already 2000 
with a publication peak in 2006. This included claims of early cancer detection on the 
basis of very low resolution MALDI spectra using ‘serum patterns’, rather than actual 
protein identifications (Petricoin et al., 2002). It was later shown that biases in the 
experimental procedures were responsible for the claimed classification success and 
this resulted in a severe setback for plasma proteomics (Baggerly et al., 2004). The next 
period with increasing numbers of publications extends from 2009 to 2013, followed by 
stagnation, presumably due to the fact that no new biomarkers had been discovered. 
The number of publications remains low and even dropped to a minimum in 2016. This 
becomes even more remarkable against the backdrop of an ever expanding community 
of researchers using proteomics and their steadily increasing output of publications. 
Today, relatively few groups continue to pursue plasma proteomics, despite the 
undiminished medical need for new biomarkers and the success of MS-based 
proteomics in other areas. This raises the question of what holds back the field of MS-
based plasma proteomics.  
 
1.4.1.2. Technological limitations 
Finding new biomarker requires high samples throughput to obtain statistically robust 
results. However, in current MS-based proteomics, the preparation of peptides from a 
biological sample typically requires more than 24h and long, 2-4h gradients are usually 
employed. Furthermore, sample preparation workflows are not standardized, much less 
over a period of years. Plasma contains lipids and other small molecules that act as 
impurities or contaminants in proteomic workflows, if not removed. This can result in 
clogging of the HPLC columns that are coupled online to the MS as well as in frequent 
cleaning of the instruments. Together, this has made plasma proteomics very time 
consuming and expensive. Clearly, proteomics based biomarker research requires a 
robust, highly reproducible and ideally automatable workflow. Such a workflow should 
allow the preparation of large numbers of samples in a short time and their highly 
reproducible measurement, without down time of the instrumentation.  
Plasma is generally considered to be the most complex of all body tissues for proteomic 
analysis, due to its high dynamic range of at least ten orders of magnitude combined 
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with the need for very high sensitivity. This restricts analysis of the plasma proteome to 
about six to seven orders of magnitudes with current state of the art instruments. As LC-
MS/MS is based on peptides that are separated by a gradient and that elute in a time-
ordered manner from the column, co-elution and electrospray ionization of very highly 
abundant and low abundant peptides decreases the probability to detect the low 
abundant ones. In plasma, the 41 tryptic peptides of serum albumin or the 312 peptides 
of apolipoprotein B (fully tryptic peptides with 7-30 amino acids) present particular 
challenges because of their extreme abundances and high numbers. On Orbitrap 
analyzers, in particular, the space charge limit of the ion trap can be almost completely 
taken up by such abundant peptides in a very short time (< 1 ms), ‘crowding out’ the low 
abundant ones.  
 
1.4.1.3. Cohort intrinsic problems 
Another problem for biomarker discovery is the fact that the levels of plasma proteins 
can be individual-specific. This can be genetically determined, for instance the 
concentration of the above-mentioned apolipoprotein(a) decreases with increasing 
numbers of kringle IV domains and the levels of pregnancy zone protein (PZP) are 
gender specific (Christensen et al., 1989; Utermann, 1989). Despite its potential impact, 
this issue has rarely been recognized by the community before being recently addressed 
by MS-based proteomics (Geyer et al., 2016a; Geyer et al., 2016b; Liu et al., 2015). 
Another, often neglected issue in clinical studies is the sample quality (Hassis et al., 
2015; Kaisar et al., 2016). Samples may be collected by medical doctors that are under 
constant time pressure and whose primary aim is to take care of patients. Quality cannot 
always be guaranteed under such circumstances, calling for markers to identify 
problematic samples.  
The very design of proteomics based biomarker studies can also be an issue. Our 
literature search revealed that only 47% of the studies had any kind of validation of the 
results in the discovery phase (Figure 6 A). In half of the cases the follow up experiments 
were simple western blots or immunoassays of candidate proteins performed with the 
same sample rather than an independent cohort. Moreover, in 30% of all studies, cases 
and controls were pooled (Figure 6 B). This is usually a consequence of the low 
throughput of the workflow employed but is justified by the argument that it will reduce 
individual specific differences (Weinkauf et al., 2006). However, proteins such as 
pregnancy zone protein or the clinically important C-reactive protein (CRP) can be 
10,000 fold increased in single individuals, skewing the levels in the entire pool. I found 
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similar concentration differences for quality marker like carbonic anhydrase 1 (CA1), 
indicating erythrocyte lysis (Geyer et al., 2016a). Even more problematic, several 
studies in our literature search reported these quality markers as potential biomarkers. 
Furthermore, pooling can remove subgroup specific effects in a cohort, which are by 
definition the basis of personalized medicine. For example, the discovery that HER2/neu 
was expressed in just 30% of women with breast cancer enabled the therapeutic 
antibody Herceptin to pass all clinical phases, whereas a pooling strategy might have 
denied patients this lifesaving therapy (Ullrich et al., 1984).  
 
 
 
Figure 6: Literature review. (A) Pie chart of the proportion of studies, using discovery and validation 
phases. (B) Percentage of studies investigating pooled samples. 
 
1.4.1.4. Traditional plasma proteomic workflows 
Proteomic researchers are accustomed to large numbers: in a standard preparation of 
cancer cell lines like HeLa, it is readily possible to identify more than 40,000 peptides, 
corresponding to more than 4,000 proteins using 2h gradients on quadrupole-Orbitrap 
instruments (Q Exactive HF). This can even be increased to more than 10,000 proteins 
and 100,000 peptides with more elaborate workflows (Bekker-Jensen et al., 2017; 
Geiger et al., 2012; Kulak et al., 2017). In stark contrast, we could only detect around 
2,000 peptides and 200 proteins with very similar workflows and more elaborate 
versions did not drastically improve those numbers. This was mainly due to the extreme 
dynamic range in conjunction with sensitivity challenges as mentioned above.  
To partially overcome this challenge, researchers have applied very extensive 
fractionation and depletion of the most abundant plasma proteins. Sample pre-
fractionation can easily be implemented, but decreases throughput and reproducibility, 
drawbacks that are especially problematic for biomarker studies. The aim of depletion 
is to remove high abundance proteins from plasma and thereby to enrich the lower 
abundant and potential more interesting ones. There are two common strategies: The 
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first is based on ‘ProteoMiner’ hexa-peptides that are immobilized on beads 
(Thulasiraman et al., 2005). Proteins bind to the hexa-peptides with different 
probabilities, partially ‘randomizing’ the plasma proteome. The second strategy uses 
bead-immobilized antibodies against the most abundant plasma proteins. Target 
proteins bind to the antibodies and the unbound portion can be collected and analyzed. 
Different vendors sell depletion kits for the highest 1, 2, 6, 12, 14 or even 20 proteins 
(called top X depletion). Using a combination of immunodepletion and extensive 
fractionation has led to the identification of more than 1,000 (Addona et al., 2011; Cao 
et al., 2012; Paczesny et al., 2010) or even more than 5,000 proteins in plasma 
(Keshishian et al., 2015). The latter number was achieved with so-called ‘supermix 
depletion’, which pushes this technique to its extreme (Qian et al., 2008). The polyclonal 
antibody mixtures used in chromatographic supermix depletion are generated by 
immunizing hens with top 14 depleted human plasma and subsequently purifying IgY 
antibodies from eggs.  
Although attractive in principle, depletion suffers from unspecific removal of proteins 
cross-reacting with the antibody targets or sticking to the chromatographic material. This 
problem can be illustrated by comparing our deepest dataset from undepleted plasma 
samples of a cohort of more than 40 individuals to a much used plasma dataset with 
supermix depletion of four individuals (Keshishian et al., 2015). Notably, this resulted in 
poor correlation over the entire abundance range with an R2 value of only 0.23. Proteins 
were separated into two clouds, the lower of which is presumably caused by unintended 
‘off target’ depletion. There are even proteomic researchers who endeavor to identify 
the hundreds of proteins bound to albumin – the ‘albuminome’ – and who also discuss 
the effect of albumin depletion on the plasma proteome (Gundry et al., 2007; Gundry et 
al., 2009; Holewinski et al., 2013; Lowenthal et al., 2005). Moreover, depletion columns 
can be very expensive (2,000-31,000 €) and are only intended to be used for up to 200 
depletions. Their efficiency will also change uncontrollable over time, making the 
reproducible analysis of large cohorts very difficult. That said, applying depletion 
strategies very carefully to a strictly controlled set of samples can be a suitable means 
to reach a sufficient proteome coverage for biomarker discovery (Keshishian et al., 2015; 
Li et al., 2013), however, results should be verified and validated in independent cohorts 
(Rifai et al., 2006). In this thesis, depletion is used only for the generation for ‘plasma 
peptide libraries’.  
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Figure 7: Correlation of an undepleted to a depleted plasma proteome. Correlation of a dataset 
resulting from  supermix depletion of four individuals  (Keshishian et al., 2015), to our deepest, quantitative 
Plasma Proteome Profiling dataset of 47 study participants. This resulted in two populations of proteins, of 
which the red population was decreased in the supermix depletion dataset, presumably due to unintended 
de-enrichment. 
 
A survey of the literature revealed that biomarker research has so far focused on areas 
that reflect diagnostic interests of the medical community rather than current 
technological possibilities of plasma proteomics: About one third of all publications deal 
with cancer, followed by cardiovascular diseases, topics in human physiology, 
inflammation, diabetes and Alzheimer´s disease. Even with a combination of a supermix 
depletion strategy with extensive fractionation, it is still questionable if the very high 
proteome coverage and sensitivity that would be required for some of these diseases 
could be reached.  
The decrease in throughput inherent in fractionation can partially be recovered by 
multiplexing. After digestion, peptides can be chemically labeled with isobaric tags such 
as iTRAQ or TMT (Bantscheff et al., 2008). The tags are constructed such that they add 
to the same total mass but give rise to different low mass reporter ions. Generally, 
between four and ten samples can be combined with such a strategy. Quantification is 
achieved by fragmenting the peptides and quantifying the relative ratios of low mass 
reporter ions. To date, a major disadvantage of these techniques is the ‘ratio 
compression’, the distortion of the peptide ratios caused by co-isolated peptide species 
that contribute to the same reporter ion. In principle this can be addressed by more 
elaborate scan modes such as MS3 (Ting et al., 2011), but currently at the cost of speed 
and sensitivity.  
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Partly as a consequence of the demands on instrument time, rarely more than 30 plasma 
samples have been analyzed at a time and only 5 studies exceeded more than 500. 
Thus the number of proteins that are measured by proteomics results in a severe 
challenge of multiple hypothesis testing, which becomes the more problematic that the 
protein numbers exceed the sample numbers. As a consequence, most studies only 
report ‘potential biomarkers’. Rigorous follow up experiments would be required to 
confirm these potential biomarkers in independent cohorts. However, usually the only 
verification has been the re-measurement of the same cohort by another technological 
platform like MRMs or immuno-assays.  
In summary, technological limitations, unawareness of potential pitfalls and issues in 
study designs have all contributed to prevent the identification of true biomarkers so far.  
 
1.4.2. The ‘triangular strategy’ for biomarker research 
By its nature, MS-based discovery proteomics is a hypothesis free approach with no 
assumptions regarding the origin or identity of possible biomarker candidates. This is in 
contrast to the analysis of single proteins by immunoassays or targeted proteomics, 
which are always hypothesis driven. Therefore, in principle MS-based proteomics 
should be an ideal tool for the discovery of novel biomarkers. In reality, however, the 
above-mentioned challenges have so far prevented the identification and validation of 
biomarkers by proteomics. 
As mentioned, the low sample throughput in relation to the number of quantified proteins 
has resulted in a division of the biomarker research process into several steps. The 
resulting ‘triangular strategy’ is generally accepted as the gold standard for biomarker 
discovery (Rifai et al., 2006). In this strategy, the number of individuals increases over 
three study phases from just a few to several hundreds, whereas the number of 
investigated proteins decreases from up to several thousands to one or a few proteins. 
This results in a triangular shape for the numbers of study participants and an inverted 
triangle for the number of proteins (Figure 8).  
 
          1. Introduction 
                                                                                                                                                         19 
 
 
Figure 8: Triangular workflow for biomarker discovery. The triangular strategy is based on three phases 
with increasing numbers of samples and decreasing numbers of investigated proteins over the different 
stages. In the discovery phase, plasma of a small cohort is harvested and typically depleted of the highest 
abundant proteins (blue). The remaining proteins (red) are digested to peptides, which are optionally labeled 
with isobaric tags for multiplexing. Peptides of different individuals labeled with unique heavy isobaric tags 
are combined and fractionated. Each fraction is separately measured by LC-MS/MS. Next, the raw data are 
processed and analyzed to find new biomarker candidates. In the verification phase, targeted proteomics 
is applied. Ideally, heavy labeled peptides of the targeted proteins are added as internal standards for 
absolute quantification. Fractionation is applied to quantify low abundant proteins but multiplies the number 
of required measurements. Triple quadrupole MS are the typical MS instruments for targeted analysis. In 
the validation phase, one or a small number of biomarker candidates are screened by immuno-assays 
against individual proteins in a large cohort. In enzyme-linked immunosorbent assays (ELISA), antibodies 
bind the candidates (red) and non-bound proteins (blue) are removed. A secondary antibody linked to a 
reporter-fluorophore is used in a sandwich configuration for specific quantification. Proteins that significantly 
discriminate between cases and controls would be considered as true biomarkers. 
 
In the first – discovery – phase, shotgun proteomics is applied using the above 
mentioned strategies with low sample throughput and with a proteomic coverage that is 
as high as possible. Typically, this stage results in a smaller number of proteins (~10s) 
that are termed as ‘potential biomarker’ or ‘biomarker candidates’, which refers to the 
need of further evaluation in the second – verification – phase, preferably in a larger and 
independent cohort compared to the discovery phase. This stage can also be done by 
MS, however, employing medium-throughput and targeted techniques such as multiple 
reaction monitoring (MRM), (Carr et al., 2014; Ebhardt et al., 2015). In MRM, one or 
more unique peptides for each biomarker candidate are selected and their 
characteristics like retention time and optimal fragmentation energy are experimentally 
determined to establish the MRM assay. In principle, as the MS is only focusing on a 
small number of peptides, high sensitivity and accurate quantification can be achieved 
with less extensive sample preparation steps, resulting in higher throughput. Even 
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though inter-laboratory studies have achieved good reproducibility in proof-of-principle 
studies (Abbatiello et al., 2015; Addona et al., 2009), the reported sensitivities do not 
reach the low ng/mL concentration range and demonstrated multiplexing capabilities are 
typically less than 50 peptides (Oberbach et al., 2014; Percy et al., 2013; Shi et al., 2013; 
Wu et al., 2015). Absolute quantification of individual proteins is preferable to relative 
quantification and this can be achieved in a highly accurate manner with internal 
standards. For this purpose heavy isotopically labeled, synthesized peptides are 
typically used. Even more accurate would be the addition of recombinant expressed 
proteins (SILAC-PrESTs) to the sample before digestion to control for variations during 
the complete workflow from adding the first buffers to the sample until the MS 
measurement (Edfors et al., 2014; Geyer et al., 2016a; Zeiler et al., 2012). The last step 
in the triangular strategy is the validation phase and its purpose is the further evaluation 
of the biomarker candidates that have passed the previous stages. The great advantage 
of immunoassay in this phase is their high throughput combined with high sensitivity, 
which enables testing candidates in hundreds or even thousands of samples. However, 
establishing specific immunoassays is time-consuming and far from trivial. Note that this 
‘gold standard triangular strategy’, is quite demanding and that there are few if any 
examples, where it has been applied in its entirety.  
The lack of success in finding new biomarkers resulted in many recommendations for 
proper study design, quality standards, workflows and evaluation of results (Hoofnagle 
et al., 2016; Luque-Garcia and Neubert, 2007; Mischak et al., 2010; Parker and 
Borchers, 2014; Paulovich et al., 2008; Skates et al., 2013; Surinova et al., 2011). 
However, this just serves to underline the fact that there are still no validated plasma 
biomarkers that had been discovered by proteomics.  
 
1.4.3. Plasma Proteome Profiling  
 
1.4.3.1. The Concept 
The technological developments in our departments before and during this PhD thesis 
enabled the development of a new concept, which we termed ‘Plasma Proteome 
Profiling’, a novel way to attack the plasma proteome with a systems-wide view. Our 
primarily aim is not necessarily to find new biomarker per se, but to establish a powerful 
way for deep phenotyping of humans. With Plasma Proteome Profiling, we wish to obtain 
a better understanding of human biology, starting from basic questions like how the 
plasma proteome responds to different environmental influences such as simple life 
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style changes and continuing on to more complex processes, for example disease 
progression or the response to a treatment. Our principal strategy is to gather as much 
information on as many proteins over as many conditions as possible. Apart from 
reviving biomarker research, a knowledgebase that integrates all this information would 
have very broad applications – ranging from the selection of optimal lifestyle changes to 
monitoring the effectiveness of medical interventions. Storing information about protein 
changes in response to widely different circumstances would also help to evaluate 
biomarker candidates of any particular clinical study. Below we describe how some of 
our proteomics quality panels could have helped to discard biomarker candidates 
already in the discovery phase of other studies. This would have eliminated time 
consuming and costly follow up. In my own work, I was able to combine the results from 
two studies to differentiate between the effects of caloric restriction and bariatric surgery 
induced weight loss and to address one of the major questions in the field of human 
metabolism from a novel angle (Albrechtsen et al., 2017). 
 
 
Figure 9: A ‘rectangular strategy’ evolved from the Plasma Proteome Profiling concept. (A) In the 
rectangular strategy, many individuals will be screened by Plasma Proteome Profiling, resulting in 
quantitative information about a large number of proteins. Two independent cohorts are measured and 
potential biomarkers must be significant in both of them. In the validation and implementation phase. The 
biomarker candidates can then be validated in yet another cohort, and clinically implemented either in the 
same form as in the discovery phase or with spike-in internal standards (SILAC-PrESTs). (B) Plasma 
Proteome Profiling aims at the high throughput screening of as many proteins and in as many conditions 
as possible in large studies. This would result in a large ‘knowledge-base’ with quantitative information – 
ideally about all proteins and conditions. Data mining can be used to interpret an individual’s Plasma 
Proteome Profile and disentangle the possible influences that add up to his or her health and disease state 
(a human phenotype). Adapted from (Geyer et al., 2017). 
 
This concept of deep phenotyping humans is in stark contrast to the current gold 
standard for biomarker discovery or plasma proteomics described above. One of the 
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main requirements to asses many conditions is to create a high throughput plasma 
proteomics pipeline. Such a pipeline must be very robust and reproducible to deliver 
highly accurate and valuable information. The combination of very robust and accurate 
measurements with a deep proteome coverage would make such a strategy very 
interesting for biomarker discovery and could even result in a change of the current 
paradigm for finding biomarkers.  
There is a similarity to other technologies that evolved from low to high throughput 
workflows such as genome-wide association studies (GWAS). Because of the high cost 
of genotyping, which necessitates determination of thousands of potential genetic 
markers in thousands of subjects, researchers traditinally followed a workflow similar to 
the triangular one in proteomic biomarker studies (Satagopan et al., 2002; Thomas et 
al., 2004). This involved genotyping a few samples on many markers at first, followed 
by validation of a smaller number of candidate markers in a larger cohort in a second 
phase to reach statitistically significant results. It was then demonstrated that jointly 
analyzing data from both stages would nearly always increase statistical power 
compared to the two step approach (Skol et al., 2006), and this strategy has been 
adopted in subsequent GWAS studies. A high throughput plasma proteomics pipeline 
would allow us to implement a similar strategy, where discovery and verification are 
handed in parallel and are followed by a verification and implementation phase.  
Even in the proposed rectangular strategy, a multi-phase approach will still be 
indispensable to verify results in independent cohorts to control for study-specific effects 
and biases. However, our high throughput plasma proteomics pipeline would allow us 
to shift from the classical triangular to a rectangular workflow. In this new strategy a 
large number of proteins would be quantified across a large number of samples, which 
would result in much stronger candidates for the following validation phase(s) (Figure 9 
A). Instead of a discovery study that is followed by a verification phase, Plasma 
Proteomic Profiling is applied to two large and independent cohorts, neither of which is 
privileged over the other. The set of overlapping, significant proteins then constitutes the 
verified biomarkers. In addition to delivering more robust ‘first phase candidates’, this 
approach offers the opportunity to verify several biomarkers at once. Repeating this 
process in many studies for a large diversity of conditions will by itself build up the 
‘knowledge base’ described above, that connects the plasma proteome to actionable 
human phenotype information (Figure 9 B).  
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1.4.3.2. Sample preparation 
MS-based proteomic workflows consist of multiple steps, namely sample preparation, 
on-line liquid chromatography, MS measurements, followed by computational data 
analysis and bioinformatics interpretation. The extensive sample preparation procedure 
begins with the extraction and solubilization of proteins, followed by denaturation, 
reduction and alkylation of cysteine residues and enzymatic digestion. The peptides are 
cleaned up and separated by long gradients (2-4h) where the HPLC is on-line coupled 
to electrospray ionization and data acquisition by the mass spectrometer. In contrast to 
such workflows, which usually aim to maximize protein identifications, we here focused 
on quantitative accuracy and throughput to develop a rapid, robust and highly 
reproducible workflow from sample preparation to data analysis that could be used for 
clinical applications.   
By optimizing the digestion buffer system, Kulak et al. simplified the sample preparation 
protocol, removed bias prone precipitation steps and increased digestion rates (Kulak 
et al., 2014). To obtain an even more rapid workflow, I further removed unnecessary 
steps like repeated sample boiling, ultrasound-treatment and overnight digestion. 
Further minimization of starting material allowed decreasing the amount of expensive 
digestion enzymes and the combination these (trypsin and LysC) in the same digestion 
mixture increased throughput and proteome coverage. Using this protocol we observed 
that suitable digestion occurred already after 1h with low ‘missed cleavage rates’, similar 
to the standard overnight digestion, and very low coefficients of variations (CVs) for the 
majority of all proteins. 
Contaminants that can result in clogged HPLC columns and frequent cleaning cycles of 
the MS cause increased instrument down times and low sample throughput. Therefore, 
one of our main objectives was to establish optimal washing conditions for peptide 
cleanup. This was achieved by extensive testing of a large variety of solvents and 
mixture conditions as well as different solid phase extraction matrices. The washing 
procedure need to remove interfering buffer components, lipids and other contaminants, 
yet retain the peptides. The final protocol combined one solvent condition with extensive 
mixing of the digest with the washing buffer (100 pipetting cycles) and a particular solid 
phase extraction matrix (polystyrene-divinylbenzene – reverse phase sulfonate, SDB-
RPS). Mixing dissolves all contaminants and makes it possible to separate them from 
the peptides by a cleanup over the solid phase extraction matrix which retains peptides.  
Next we wished to improve reproducibility and high throughput by automation. For this 
purpose, we installed an Agilent Bravo liquid handling system with disposable pipet tips 
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and transferred our protocol to this platform. The robotic protocol was optimized and 
evaluated over several month, resulting in a reproducible, reliable and error-free system. 
I developed several liquid handling schemes, starting with finding optimal lab-ware that 
does not introduce polymers or absorbs peptides during processing. Pipetting strategies 
like pre and post air aspiration and tip touch procedures for highly accurate handling of 
small volumes were incorporated. Further adjustments of sample volumes as well as 
the washing buffers were necessary to transfer the protocol to the robotic platform.  
The following statistics illustrate the initial challenges that we were facing and the 
progress that we have made: Prior to optimization, a single cleanup workflow needed 
24-48h and we were only able to analyze 20-30 samples before contaminants led to 
deterioration of our HPLC system. Today, we prepare 96 samples in a fully-automated 
manner within 3h and we regularly measure hundreds of samples without any problems. 
This decreases hands-on time, which can be spend on data analysis instead, improves 
reproducibility, and makes optimal upkeep of expensive mass spectrometers much less 
stressful.  
We termed our concept of analyzing whole, undepleted plasma in a rapid manner with 
a very robust and reproducible workflow, ‘Plasma Proteome Profiling’ and described it 
in a manuscript that became the featured article in the journal Cell Systems (Geyer et 
al., 2016a).  
 
1.4.3.3. LC-MS/MS optimization 
The optimization of sample preparation described above was the first step necessary 
for the analysis of large cohorts. It enables high throughput on the sample preparation 
side by preparing purified peptides in a short time that are ready for MS-analysis. 
However, typically MS-based proteomics is maximized for the number of proteins that 
can be identified and this usually entails long HPLC gradients, which would impede 
throughput. In highly complex samples with hundred thousands of peptides like cell lines 
or tissues, long gradients provide the peptide fragmentation time necessary for high 
proteome coverage. In plasma, in contrast, there are just thousands of peptides in a 
sensitivity range that makes them accessible to MS1 and MS2 analysis. As a 
consequence, we found that shorter gradients result in nearly the same number of 
identified proteins. In particular, a 20 min gradient lost only 5% of protein identifications 
compared to the standard 100 min gradient (Geyer et al., 2016a). We then investigated 
increasing the flow rate, decreasing loading volumes, optimizing gradients and 
shortening the HPLC column length to assure optimal usage of the short gradients. In 
          1. Introduction 
                                                                                                                                                         25 
this way we are now able to analyze almost 50 samples per day. Later we also 
implemented DMSO as an additive to increase peptide ionization efficiency (Hahne et 
al., 2013). 
One disadvantage of short gradients is that they use the MS instruments inefficiently. 
Even after optimization, loading and equilibration requires more than 10 minutes on 
high-end HPLC systems, which for the 20 min gradients, would mean that the mass 
spectrometer is unused a 1/3rd of the time. This could potentially be avoided by more 
sophisticated LC set ups, but here we decided to increase utilization of the MS 
instrument time with a somewhat longer gradient (45 min; about 24 samples/day) and 
combine this with the ‘library matching’ approach, that will be explained below. 
 
1.4.3.4. Library matching strategy 
Data-dependent acquisition strategies use a combination of MS1 and MS2 scans. 
Following their detection in the MS1 spectra, peptide precursor ions are ranked by 
intensity and the analytical quadrupole selects them in this order with a small isolation 
window (typically 1.4 Th) centered on the measured m/z. The peptides are fragmented 
in the collision cell and the masses of these fragments are recorded with high accuracy 
in the Orbitrap analyzer. Precursor mass and fragment masses are then used in a 
database search to determine the sequence and therefore the identity of the peptide. 
Because relative peptide elution varies somewhat between runs, this strategy results in 
a semi-stochastic selection of precursors depending on the intensity-based ranking (top 
N). Furthermore, the fragmentation spectra may be of sufficient quality for identification 
in one run but not another.  
Our laboratory has developed the software package MaxQuant for peptide and protein 
identification and quantitative analysis of MS data (Cox and Mann, 2008). MaxQuant 
incorporates an optional feature termed ‘match between runs’ to transfer peptide 
identification based on information about retention time and accurate m/z ratios from 
one LC-MS run where the peptide was identified by an MS2 scan to another HPLC run 
where the required MS2 data is not present (Geiger et al., 2012; Nagaraj et al., 2012). 
In plasma we observed that the matching strategy was also advantageous. However, 
because the numbers of identified peptides in the libraries was low, there were still few 
matched peptides in the single runs. I therefore acquired successively deeper plasma 
peptide libraries. The first consisted of single runs of plasma that was depleted for the 
top 6 most abundant proteins, but we then realized that the combination with a top 14 
depletion column produced superior results. Importantly, we use the libraries only for 
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matching and therefore it is not required that depletion is quantitatively accurate. In this 
way we were able to boost protein identifications by almost 40% (Geyer et al., 2016a). 
Later we combined the double depletion with high pH reversed phase fractionation 
(Kulak et al., 2017) to acquire very deep libraries of more than 1,500 proteins (see 
below). Without any matching applied, identification was limited to around 200 proteins 
in 45 min gradients. The ‘depleted library’ approach allowed us to cover more than 500 
proteins within the same time.  
To further boost the depth of the measured plasma proteome, we made use of a recent 
development in our laboratory that dramatically increases the dynamic range of 
detection in MS1 scans, which are limited to about one million ions due to space charge 
effects (Meier et al., 2017). In this ‘BoxCar’ acquisition method, the m/z range is broken 
up into multiple narrow m/z windows, which are filled with much longer injection times 
than the MS1 scan. This results in ‘normalizing’ the full scan and in effect boosts the 
intensity of low abundance ions ten-fold or more. BoxCar works particularly well in 
proteomes with a high dynamic range such as plasma where a few very high abundant 
peptides otherwise mask co-eluting, lower abundant peptides in the MS1 scan (Meier et 
al., 2017). Remarkably, combination of the above-mentioned improvements with BoxCar 
scans allowed us to identify over 800 proteins in single and more than 1,000 proteins in 
triplicate measurements. 
 
1.4.3.5. Deep quantitative plasma proteomes 
To achieve deep proteome coverage in complex biological samples, an additional step 
of peptide fractionation is widely used. Splitting a tryptic peptide mixture into several 
fractions, while loading the analytical column to capacity, will increase the detectability 
of low abundance proteins, because the peptides are separated from each other and 
more material can be injected into the MS in total. High pH reversed-phase fractionation 
in combination with concatenation as a first dimensional separation step has proven to 
be highly efficient (Delmotte et al., 2007; Gilar et al., 2005b; Manadas et al., 2009).  
Because of the larger diameter columns used, such fractionation approaches typically 
require rather large sample amounts (in the mg-range) and the concatenation procedure 
can be error-prone and time consuming. To tackle this problem, we developed a high 
pH reversed-phase fractionation and concatenation device – called ‘Spider Fractionator’ 
– for automated off-line chromatography separation of small peptide amounts (Kulak et 
al., 2017). In cell lines this approach allowed us to identify more than 150,000 peptides 
and almost 12,000 proteins with 24 fractions. In plasma, I used several depleted plasma 
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samples and constructed a library of 2,000 proteins, reflected by 14,000 sequence 
unique peptides. 
For the physiological interpretation of protein levels in plasma, we also wished to 
construct a deep quantitative plasma proteome. With eight ‘spider-fractionations’ 
measured as singlets in 45 gradients, I quantified nearly 1,500 proteins. As expected, 
‘functional plasma proteins’ were generally of comparatively high abundance, ‘tissue 
leakage proteins’ were scattered among the middle and low abundance range, whereas 
most of the cytokines have exceedingly low levels in normal plasma and were therefore 
not detected. To my knowledge, this is the first deep and quantitative plasma proteome 
and it should be a useful resource to the community. 
 
1.4.3.6. Throughput vs. deep measurements 
In addition to the throughput required to realize the concept of Plasma Proteome 
Profiling, it clearly also requires a certain depth of coverage, to combine highly accurate 
MS acquired data with clinical data on a global scale. This mandates an optimal 
combination of throughput and proteome coverage. 
 
 
 
Figure 10: Technological developments and strategic assessments of Plasma Proteome Profiling. 
This PhD thesis started with a standard proteomic workflow in 2014. Optimizations on various stages 
allowed us to develop the Plasma Proteome Profiling concept. Implementation of further technological 
developments increased the number of identified proteins and the throughput as shown. Unless indicated 
otherwise, 45 min gradients were used. The numbers of fractions are displayed for the fractionation strategy.  
 
To visualize progress towards the goals of Plasma Proteome Profiling, one can plot the 
total number of identified proteins against the number of samples that can be measured 
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per day (Figure 10). In this plot the far right and top corner is the most desired region 
and the figure illustrates successive improvements in throughput and proteomics 
depths. With the technology developed in this thesis, we can now identify on average 
800 proteins in plasma in 45 min gradients at a throughput of 24 samples per day and 
per instrument (8 per day in case of triplicate measurements). Alternatively, collecting 4, 
6 or 8 fractions, resulted in 1160, 1429 and 1487 identified proteins, respectively. An 
optimum between measurement time and number of proteins seemed to be reached 
with six fractions. Compared to existing literature, such numbers are exceptional for 
plasma proteomics, especially taking into account that we obtain quantitative proteomes 
from undepleted plasma. However, the throughput of only four samples per day with six 
fractions is not yet compatible with our goal of analyzing large cohorts. This will require 
either an even deeper coverage in single runs or a multiplexing strategy to increase 
sample throughput after fractionation. 
 
1.4.3.7. Quality marker panels 
Samples for thousands of clinical studies are being collected at any given time 
worldwide, adding to the countless clinical studies that are already stored in biobanks 
with the aim to find biomarkers. There is a large variety of protocols for sample collection 
and storage, potentially confounding subsequent analysis. The community is acutely 
aware of these issues, but could not address them in a systematic manner so far 
(Lombardi et al., 2012; Pickup et al., 2017; Zhao et al., 2012). Given the fact that it is a 
basic requirement that the samples are of high quality and the potential for systematic 
errors to affect study outcomes, we asked whether Plasma Proteome Profiling could 
solve this issue. 
Samples of poor quality contribute to the variation between individuals, one of the major 
focus areas in biomarker research (Mischak et al., 2010; Surinova et al., 2011). The 
small discovery cohorts in the triangular strategy of biomarker research are especially 
prone to suffer from samples with poor quality. As pointed out above, it is a wide-spread 
practice to pool clinical samples within case and control groups to decrease 
measurement time and “equalize” individual-specific differences. The danger in such 
practices lies in single contaminated samples that can result in a systematic bias. Our 
literature search illustrated the dimension of the problem, and suggests that a sizable 
proportion of the literature has reported potentially incorrect results because of this.  
According to the same literature search, shotgun proteomic results are often ‘verified’ in 
the same cohort just with a different technology. Importantly, proteins enriched in case 
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or control solely due to quality issues, can still pass such experimental designs and may 
be considered for further validation in larger, time and cost intensive cohorts. 
Furthermore, genuine biomarkers may be obscured by protein variation introduced 
through quality issues. In view of these issues, it is unfortunate that to date, there are 
no protein-based markers available to monitor the quality of blood-based samples. This 
is in contrast to the situation in metabolomics, which faces the same challenges. Here, 
it is possible to assess some quality criteria with a metabolomics-based marker panel, 
which take blood coagulation and storage time into account (MxP Quality Control 
Plasma (Kamlage et al., 2014)). However, this test does not consider the blood sampling 
procedure, erythrocyte contamination and is restricted to EDTA-plasma. 
We reasoned that the unbiased coverage of Plasma Proteome Profiling and the robust 
nature of the workflow would lend themselves to address the issue of sample quality. 
We performed a wide variety of experiments to investigate this question and uncovered 
three different kinds of sample quality marker classes: those for blood sampling 
procedure, erythrocyte contamination and coagulation. 
The first class includes all markers that originate from blood sampling. Blood taking with 
different equipment, including needles with different diameters, collection tubes and the 
use of products from different vendors can all influence results. In daily clinical practice, 
blood is sampled by trained nurses, medical doctors, but also by rather untrained 
medical personal like students, contributing to this class of quality issues. We reasoned 
that smooth muscle and endothelial cell specific proteins would be candidates for this 
class of markers. Each blood vessel consists of different layers. The outer ones consist 
of smooth muscle cells and the inner one of endothelial cells. The above mentioned 
issues can lead to the collection of different proportions of these cell types together with 
the blood. To investigate this at the protein level, we looked for smooth muscle and 
endothelial cell specific proteins (SMECs) in our datasets and confirmed them by 
analyzing the proteomes of blood vessels from humans (Figure 11 A, B). 
Erythrocytes are the dominant cell type in our blood stream. Blood is centrifuged to yield 
plasma or serum, which are the preferred matrices for clinical tests. Delay in the time 
until start of centrifugation, inappropriate centrifugation speed and time, handling, 
transportation, harvesting of the separated plasma and recontamination after 
centrifugation may all result in variable presence of highly abundant erythrocyte-specific 
proteins (HAEP) in plasma. This is especially striking when plasma is repeatedly 
harvested from the same person (Figure 11 C). We used spike-in experiments to identify 
HAEP panels and were able to quantify HAEPs down to an erythrocyte to plasma ratio 
of 1:10.000 (Figure 11 D) (Geyer et al., 2016a). 
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Activation of the coagulation cascade is necessary to produce serum from blood. In 
contrast, to obtain plasma, blood must be instantly mixed with an anti-coagulant, 
otherwise partial coagulation will result. To find markers for unintended blood 
coagulation, we compared serum to plasma from the same individuals. The levels of 
fibrinogen alpha (FGA), beta (FGB) and gamma (FGG) chains were decreased and the 
platelet-specific proteins platelet factor 4 variant (PF4V1) and platelet basic protein 
(PPBP) were increased in serum compared to plasma (Figure 11 E, F) (Geyer et al., 
2016a). Using the coagulation influenced proteins (CIP) as a quality panel, we have so 
far detected systematic bias in one out of 13 studies. 
 
 
 
Figure 11: Quality marker panels. (A) Smooth muscle and endothelial cell (SMECs) protein markers (red) 
are among the highest abundant proteins in the blood vessel proteome. Proteins are ranked according to 
their abundances. (B) Volcano plot comparing two time points (1 vs. 2) of a clinical study that had a bias, 
indicated by increased levels of SMECs (red). (C) Scatterplot of repeated finger pricks of one individual 
(replicate 2 vs. replicate 3) showing that erythrocyte-specific proteins were elevated as a group of four 
proteins. HBA1, hemoglobin subunit alpha; HBB, hemoglobin subunit beta; HBD, hemoglobin subunit; CA1, 
carbonic anhydrase 1. (D) Spike-in of erythrocytes into plasma resulted in an increase of these proteins as 
a group. (E) In a comparison of plasma and serum of two individuals, the levels of FGA, FGB, and FGG 
were decreased, and PPBP as well as PF4V1 were elevated in serum. FGA, FGB, FGG, fibrinogen chains 
alpha, beta, gamma; PPBP, platelet basic protein; PF4V1, platelet factor 4 variant. (F) Blood was processed 
from ten different fingers of one individual after finger pricking, and mass spectrometric (LFQ) intensities of 
FGA, FGB, FGG, PPBP, and PF4V1 are plotted. In samples 1 and 2, fibrinogens were decreased, whereas 
platelet-specific proteins are increased. (G) Sample quality assessment of a study consisting of 318 
samples. One protein of each quality marker panel was chosen for this illustration. The reference range of 
each marker is highlighted in the color of the quality marker class (green, yellow, red). Outliers of these 
categories, like the three indicated samples, are of poor quality. CIP: Coagulation influenced proteins; RBC: 
Red blood cell specific proteins. (C-F) were adapted from (Geyer et al., 2016a). 
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Quality marker panels would be especially valuable in hospitals for assessment of 
clinical samples and in the selection of cohorts to be used in biomarker studies. On the 
basis of such tests, clinical samples of poor quality can be discarded to avoid reporting 
incorrect clinical test results and in general as an internal quality check of the clinical 
laboratory (Figure 11 G). Assessing the quality of existing studies should drastically 
decrease the fruitless follow up of spurious biomarker candidates and conversely, it 
would increase the probability of finding real biomarkers by certifying high quality of the 
investigated clinical samples and cohorts.  
 
1.4.3.8. SILAC-PrESTs as internal standards for absolute protein quantification 
In clinical diagnostics, the quantification of the analyte of interest by immunoassays is 
almost always uses standards of known concentration for calibration (external 
reference). In contrast to immunoassays, MS-based methods can accommodate 
internal standards, promising accurate and absolute quantification. Heavy isotopically 
labeled analytes are added to the sample at the earliest possible time point of sample 
processing. As the internal standard is exposed to the same influences as the analyte, 
it automatically corrects for variations during the workflow, resulting in highly accurate 
quantification. Such MS-based assays with internal standards are already applied in 
clinical practice for small molecules, including several metabolites such as 
phenylalanine in the phenylketonuria screen for newborns. 
In a collaboration with the Uhlen group in Stockholm, our laboratory had developed 
‘Stabile Isotope-Labeled Protein Epitope Signature Tags’ (SILAC-PrESTs) for absolute 
quantification of multiple proteins (Edfors et al., 2014; Zeiler et al., 2012). They are 
constructed as fusion proteins consisting of a histidine-tag, the albumin binding protein 
(ABP) and a unique sequence stretch of the protein of interest. First, the construct is 
recombinantly expressed in E. coli in heavy labeled form, growing in media with stable 
isotope labeled amino acids and purified by the histidine-tag (Figure 12). The ABP 
enhances solubility of the recombinant proteins and is used for determination of the 
concentration of the expressed SILAC-PrESTs. In this second step, the absolute 
concentration of a ‘light version’ (not isotopically labeled) of the ABP can be determined 
very accurately. This light ABP is digested and measured together with the heavy 
labeled SILAC-PrEST and their ratio is used to calculate the concentration of the SILAC-
PrEST. The third step is the crucial one for absolute quantification. The SILAC-PrEST 
is spiked into the sample and the SILAC ratios of the PrEST peptides to the peptides of 
the target protein can be determined. Importantly, this approach is suitable for 
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multiplexing, which has already been demonstrated for 40 SILAC-PrESTs quantifying 
HeLa proteins. Multiplexed SILAC-PrEST assays could allow the absolute quantification 
of many clinical interesting proteins in single measurement instead of multiple, separate 
protein based immunoassays. 
 
 
 
Figure 12: Absolute protein quantification based on SILAC-PrESTs. (A) The albumin binding protein 
(ABP) is recombinantly expressed in E. coli growing in light amino acid containing media. It is purified with 
a His-tag and an OneStrep-tag and the concentration is determined. The SILAC-PrEST construct is 
expressed in media with heavy amino acids. After purification the SILAC-PrEST and the light ABP are 
combined and digested together. The peptides are measured in the MS and the ratios are used to calculate 
the absolute concentration of the SILAC-PrEST. (B) The SILAC-PrEST is combined with the sample of 
interest (e.g. cells or plasma) and they are digested together. The ratio of heavy to light peptides of the 
endogenous protein and its SILAC-PrEST homologous sequence are used to calculate the absolute 
concentration. 
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2. Aims of the thesis 
The overall aim of my PhD thesis was to pave the way for biomarker discovery and 
clinical applications of proteomics by precision characterization of the human blood 
plasma proteome, a major goal of mass spectrometry (MS)-based proteomics for 
decades. Due to great technological challenges, misguided concepts and study designs, 
the analysis of the plasma proteome by MS has not yet lived up to its promises: no new 
biomarkers have been discovered, plasma proteomics has not entered clinical 
diagnostics and new biologically meaningful insights have been gained. As a 
consequence of these unsuccessful efforts, relatively few groups continue to pursue 
plasma proteomics, despite its undiminished potential for research and medicine.  
One requirement for a revival of plasma proteomics would be a rapid, robust and 
reproducible workflow. Towards this aim had to tackle several challenges. First of all, 
we had to find strategies that allowed us to efficiently measure many plasma samples. 
We further had to develop sample preparation procedures and optimize them for 
reproducibility. As proteomic workflows are generally very time consuming and labor-
intensive, we streamlined the process by shortening several steps and discarding of 
others. MS-based workflows are usually also not automated, a requirement for a truly 
robust and a high throughput sample preparation procedure. Furthermore, proteomic 
LC-MS/MS systems are currently not optimized for high throughput and several 
developments were necessary to streamline this part of the workflow.  
Another major challenge of plasma is the high dynamic range of protein concentrations. 
We addressed this obstacle by developing and implementing several strategies and 
technologies like library matching, the ‘Spider Fractionator’ and ‘BoxCar’ scans, 
dramatically increasing the number of quantified proteins.  
A central aim of the thesis was to demonstrate that MS-based proteomics can be applied 
to large cohorts and that it is possible to gain biologically and medically relevant 
information. We achieved this aim with our first large scale plasma proteomic study in 
which we analyzed more than 1,000 proteomes and defined inflammatory and insulin 
resistance panels. 
The plasma proteomics community implicitly subscribes to a particular strategy in 
biomarker research, which we find to be problematic. In my PhD thesis we developed 
new strategies and concepts that set proteomics-based biomarker discovery on a solid 
foundation. 
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3.1. Article 1: Plasma Proteome Profiling to Assess Human 
Health and Disease 
 
Authors: Philipp E. Geyer1,2, Nils A. Kulak1, Garwin Pichler1, Lesca M. Holdt3, 
Daniel Teupser3, and Matthias Mann1,2 
1Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany  
2NNF Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark  
3Institute of Laboratory Medicine, Ludwig-Maximilians-University Munich, 80539 Munich, Germany 
 
In my manuscript ‘Plasma Proteome Profiling to Assess Human Health and Disease’, I 
tackle directly many issues in the analysis of plasma proteomes like the labor-intensive 
workflow, problematic contaminations, sample quality assessment and the analytical 
variability. I streamlined the proteomic workflow, resulting in a rapid, robust and highly 
reproducible pipeline, which was further automated by implementing it on a liquid 
handling platform. Optimization of digestion conditions, peptide clean-up procedures 
and LC-MS/MS settings enables us to prepare 96 samples in a fully-automated manner 
within 3h. We now regularly measure hundreds of samples without any problems. The 
high throughput of this technology opens up for new concepts in biomarker discovery, 
which we describe more fully in our review article ‘Revisiting Biomarker Discovery by 
Plasma Proteomics’ later in this thesis. 
We call our technology for the analysis of blood and its derivatives ‘Plasma Proteome 
Profiling’. This term is meant to imply that the information of the plasma proteome can 
mirror human physiology. Our pipeline offers highly reproducible and quantitative 
information for several hundred proteins (CV<20% for most proteins), including more 
than 40 clinical applied biomarkers from a single fingerprick with a 30 minute 
measurement. The quantified proteins include inflammatory markers, proteins belonging 
to the lipid homeostasis system, gender-specific proteins, disease relevant allele 
variations and quality markers.  
Furthermore, we provide proof-of-principle to transfer Plasma Proteome Profiling into 
clinical practice by introducing a SILAC-PrESTs panel of five proteins to plasma 
samples. These were used as internal standards, controlling variations during the entire 
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sample preparation workflow and allowing accurate relative as well as absolute 
quantification. 
This manuscript was the featured article in the journal Cell Systems and it was described 
as one of the journals highlights in the 2016 end-of-the-year review and it is also one of 
three listened article on the homepage of the Human Plasma Proteome Project. In our 
laboratory we are building on the developments described in this article to assess human 
health and disease states with the aim to fundamentally alter biomarker research and 
clinical diagnostics.
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3.2. Article 2: Proteomics Reveals the Effects of Sustained 
Weight Loss on the Human Plasma Proteome 
 
Authors: Philipp E. Geyer1,2,†, Nicolai J. Wewer Albrechtsen2,3,4,†, Stefka Tyanova1, 
Niklas Grassl1, Eva W. Iepsen3,4, Julie Lundgren3,4, Sten Madsbad4,5, Jens J. 
Holst3,4, Signe S. Torekov3,4, and Matthias Mann1,2 
1Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany  
2NNF Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark  
3Institute of Laboratory Medicine, Ludwig-Maximilians University Munich, 80539 Munich, Germany 
†These authors contributed equally to this work. 
 
The ‘weight loss study’ is our first clinical study, and it demonstrates that Plasma 
Proteome Profiling can live up to its promises. Before it was neither possible to measure 
large cohorts nor to find biological meaningful information in the plasma proteome. In 
this study we analyzed the largest cohort in the field of plasma proteomics with almost 
1,300 separately prepared and measured plasma samples. 
Weight loss and sustained weight maintenance are of central concern in modern society, 
research and medicine. Obesity and the metabolic syndrome are major public health 
burdens, predisposing to several diseases, including type 2 diabetes and cardiovascular 
diseases and increasing the overall likelihood of early death. However, not everyone 
agrees on how universal the positive effects of weight loss on cardiovascular and 
metabolic risk factors are. We investigated a longitudinal cohort of 52 obese study 
participants by measuring their plasma proteomes over an initial weight loss period of 8 
weeks, followed by one year of weight maintenance.  
Applying a matching library strategy by using double depleted plasma, we were able to 
quantify 437 proteins per individual. The obtained Plasma Proteome Profiles revealed 
the comprehensive systemic effects of weight loss on individual plasma proteins: Of a 
total of 737 investigated proteins, 63 were decreased and 30 were increased directly in 
response to weight loss. The longitudinal study design allowed us to monitor long-term 
regulation of proteins. We were able to follow the reduction of fat mass by the adipocyte 
secreted protein SERPINF1 which – together with the apolipoprotein F (APOF) – was 
the most significantly regulated protein in weight loss. Comprehensive quantification of 
18 members of the apolipoprotein family – the main lipid homeostasis mediators – 
delivered information on metabolic and cardiovascular risk factors that were strongly 
influenced by weight loss.  
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The meta-data available in the study supplied us with physiological and clinical 
laboratory parameters, which we correlated with the plasma proteomes, establishing 
novel dependencies. Remarkably, a panel of eight plasma proteins showed a higher 
correlation with insulin resistance than the known biomarker adiponectin. Moreover, we 
defined an inflammation panel consisting of proteins that was assessed for each study 
participant. By combining these data on an individual-resolved level, we connected low-
grade inflammation and insulin resistance. Most of the individuals with high levels of 
inflammation also had an unfavorable insulin resistance profile, but importantly, 
individuals in all groups benefited from weight loss. 
With this study we demonstrated that it is possible to measure large cohorts and to 
extract biologically and medically meaningful information in the human plasma 
proteome. Another aim of this study was to identify bottlenecks for further optimization. 
In this regard, we found that most of the down time was caused by HPLC issues that 
were not connected to the sample quality itself. Higher robustness in this area would 
directly result in higher throughput and clinical applicability.   
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3.3. Article 3: Loss-less Nano-fractionator for High Sensitivity, 
High Coverage Proteomics 
 
Authors: Nils A. Kulak1,†, Philipp E. Geyer1,2,†, and Matthias Mann1,2 
1Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany  
2NNF Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark  
†These authors contributed equally to this work. 
 
Pre-fractionation of peptides is a key enabler for the very deep and large-scale proteome 
characterization. In this manuscript we build upon the popular combination of high pH 
pre-separation in a first dimension and online low pH separation in the second 
dimension. We developed and characterized an automated rotor-valve based nano-flow 
fractionation and concatenation device, which we called ‘Spider Fractionator’.  
In existing approaches, samples are separately collected after high flow fractionation 
and afterwards combined. In contrast, the rotor valve of the Spider Fractionator 
automatically splits the flow of separated peptides after the column into time dependent 
packages, directed to a number of tubes corresponding to the number of desired fraction 
to be analyzed. The system allows the researcher many degrees of freedom for the 
experiments, e.g. the amount of fractionated material can range from just 1 µg up to 
more than 100 µg, collection of 2-96 fractions is possible and any desired time interval 
of eluting peptides can be collected. 
Instead of the typical setup for high pH fractionation, we used columns with smaller inner 
diameter, much lower flow-rates and no intermediate collection points. This makes our 
system much less prone to sample loss, which we proved by a comparison to two 
commercially available high pH fractionation systems. This analysis showed that our 
device has little if any detectable sample loss, whereas the commercial systems lost 
substantial amounts of sample during fractionation. We demonstrated that the Spider 
Fractionator enables extraordinary sensitivity: As little as one µg of peptides allowed the 
identification of more than 10,000 protein in HeLa cells after fractionation. We further 
used different fractionation strategies to obtain a deep proteome in as little time as 
possible. We applied our optimized conditions to quantify the proteomes of twelve 
human cell lines to a median depth of more than 11,000 different proteins while 
fractionating only 20 µg of starting material – by far the deepest proteome 
measurements yet achieved with such low sample amounts. This experiment also 
revealed molecular differences that recapitulated the developmental origin of the cell 
lines. 
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The ability to efficiently fractionate low sample amounts is also beneficial because a 
decrease in the starting amounts will also result in a reduction in reagent costs, which is 
especially important for samples that have been derivatized with expensive mass tags 
like iTRAQ or TMT. In our laboratory the device is now routinely used for any project 
involving pre-fractionation and it has already proven to be robust in dozens of projects. 
Together, the many advantages of using small sample amounts should make the Spider 
Fractionator attractive to the proteomics community as indicated by the fact that the 
manuscript has been downloaded more than 600 times within the first month. 
For Plasma Proteomic Profiling, the Spider Fractionator is one of the key elements as it 
enables very deep proteomes from depleted plasma samples for the library matching 
strategy and it allows us to obtain very deep quantitative proteomes by fractionation of 
undepleted samples. 
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3.4. Article 4: Revisiting Biomarker Discovery by Plasma   
Proteomics 
 
Authors: Philipp E. Geyer1,2, Lesca M. Holdt3, Daniel Teupser3, and Matthias 
Mann1,2 
1Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany  
2NNF Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark  
3Institute of Laboratory Medicine, Ludwig-Maximilians-University Munich, 80539 Munich, Germany 
 
Despite its longstanding allure, plasma proteomics has not lived up to its promise of 
revolutionizing biomarker research and clinical diagnostics. In this review we investigate 
the reasons that have held plasma proteomics back over the years. We perform a 
systematic literature research of 381 plasma proteomics publications that aimed to 
discover new biomarkers. We classify the publications by the approaches that they 
applied, such as depletion of high abundance proteins, extensive fractionation and 
chemical labeling. We evaluate problems in the design of the investigated studies, for 
example small numbers of cases and controls or sample pooling. 
This review also discusses current paradigms of biomarker research and develops 
alternative concepts. Briefly, technological progress and our high throughput plasma 
proteomics workflow enable us to pursue biomarker research with a ‘rectangular’ 
shaped process. Here, many individuals are investigated in each of the phases of the 
study by shotgun proteomics. Exploring a large cohort already at the discovery stage 
will result in much more likely biomarker candidates. The further testing of these 
candidates in a verification and a validation cohort with shotgun proteomics then 
proceeds with the testing of biomarker panels instead of individual proteins. 
Investigating as many conditions as possible for as many people and proteins as 
possible will over time generate a ‘big data’ matrix. This knowledge base itself will be an 
incomparable resource that can be mined for connections between different diseases or 
condition by advanced machine learning algorithms. It can also form the background for 
the deep phenotyping of humans.  
Moreover, we give an overview about the modern clinical laboratory, in which single 
biomarker are tested. This serves as a basis to discuss how proteomics and multi-
protein panels could be translated into clinical practice and we describe first steps in this 
direction. 
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3.5. Article 5: Ultra-deep and Quantitative Saliva Proteome 
Reveals Dynamics of the Oral Microbiome 
 
Authors: Niklas Grassl1, Nils A. Kulak1,2, Garwin Pichler1,2, Philipp E. Geyer1,3, Jette 
Jung4, Sören Schubert4, Pavel Sinitcyn5, Juergen Cox5 and Matthias Mann1,3 
1Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 
Martinsried, Germany  
2PreOmics GmbH, Am Klopferspitz 18, Martinsried, Germany 
3NNF Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, 2200 
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The concepts and much of the workflow of Plasma Proteomics Profiling can be applied 
to many other body fluids. In our laboratory we have already done this for cerebrospinal 
fluid, urine, tears and saliva. In this publication, we investigate saliva, an easily 
accessible body fluid with potential for clinical diagnostics. The oral cavity contains a 
rich community of microorganisms, which is of great current interest as the microbiome 
has a pivotal role for health and disease states. 
We describe the application of our workflow, which we optimized and streamlined for 
saliva, starting with a simple cotton swab for sample collection. In single run analysis, 
this yielded a remarkable depth of 3,700 human proteins. Moreover, we used high pH 
reversed phase fractionation for in depth characterization. This resulted in more than 
5,500 identified human proteins, which is the largest body fluid proteome so far. We 
further searched this data against a database of microbial organisms and found more 
than 2,000 bacterial proteins, originating from more than 50 genera, with a similar 
distribution between different individuals. 
Next, we applied the streamlined workflow for a first ‘clinical study’ in which eight study 
participants collected saliva in the morning before and after teeth brushing. This 
revealed drastic quantitative changes of the oral microbiome in the different individuals.  
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3.6. Article 6: HCD Fragmentation of Glycated Peptides 
 
Authors: Eva C. Keilhauer1, Philipp E. Geyer1,2, and Matthias Mann1,2 
1Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, 82152 Martinsried, Germany  
2NNF Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark  
 
High glucose level is the main symptom and diagnostic criterion of diabetes, an ever 
growing disease that affects more than 400 million humans around the globe. Today the 
gold standard for its diagnosis is to calculate the percentage of hemoglobin that has a 
distinct glycation, the so called HbA1c value.  
Glycation is a non-enzymatic reaction of glucose with amino groups of proteins, and its 
products reflect the glucose concentration in the blood stream. Because of the known 
mass that is added by the glycation reaction to lysine or arginine residues, it is possible 
to detect and quantify these products by MS-based proteomics. In the past, extensive 
sample preparation with affinity enrichment strategies have been used to identify 
glycated peptides in plasma samples. Typically, researchers employ a dedicated 
workflow to obtain the glycation information. This makes the measurement of glycation 
sites very time consuming and incompatible with high throughput measurements in the 
context of clinical or biomarker research. Furthermore, in the past specialized 
fragmentation methods, including electron transfer dissociation (ETD) were applied, 
which are only available on some MS instruments.  
In this publication we show that the standard fragmentation method ‘higher-energy 
collisional dissociation’ (HCD) alone can efficiently identify glycated peptides. We 
establish optimal fragmentation parameters and identify early glycation products on in 
vitro glycated proteins. Furthermore, we apply this workflow to plasma samples and 
detect more than 100 glycation sites in single run analysis of undepleted and unenriched 
plasma samples. We have now incorporated the identification of glycated peptides in 
our Plasma Proteome Profiling pipeline, which gives us additional information for 
biomarker research. Future research will focus on accurate quantification of glycation, 
which would allow the diagnosis of uncontrolled glucose levels in all plasma samples.  
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4. Discussion 
The majority of diagnostic decisions are made on the basis of blood-based tests, and 
protein measurements are prominent among them. However, current assays are 
restricted to individual proteins, whereas it would be much more desirable to measure 
all of them in an unbiased, hypothesis-free manner. Therefore, characterization of the 
plasma proteome by mass spectrometry holds great promise for a new era of biomarker 
research. However, MS-based proteomics has fallen short of the great expectations that 
were initially placed in it.  
This is mainly due to the tremendous technological challenges in the analysis of the 
plasma proteome, in which abundance differences between different proteins are more 
than ten orders of magnitude. In the past, researchers have followed a ‘triangular 
workflow’ in which a small cohort is measured in the discovery phase in great depth and 
differentially expressed proteins are followed up by targeted techniques in a verification 
and a validation phase (Rifai et al., 2006). The depth of proteome coverage aimed for in 
the first phase necessitated extensive fractionation and depletion, severely 
compromising throughput and quantitative fidelity and consequently no biomarkers have 
yet emerged from these approaches (Bellei et al., 2011; Keshishian et al., 2015; Li et 
al., 2013; Tu et al., 2010).  
In my PhD thesis I questioned the dogmas of current plasma proteomics and biomarker 
research. First, we set out to radically redesign proteomic workflows with a view to make 
them truly applicable to the analysis of the plasma proteome. We reduced analysis steps 
to a minimum by eliminating many of them entirely and streamlining others. This resulted 
in a rapid, reproducible and very robust pipeline, allowing the automated preparation 
and measurement of hundreds of plasma samples.  
On the basis of this new workflow, we break with previous concepts and introduce a 
‘rectangular strategy’ in which large cohorts are already explored in the first phase in as 
great a proteomics depths as is compatible with uncompromised throughput. An 
independent cohort should be analyzed at the same time and the set of proteins that are 
concordant in both sets qualify as ‘verified biomarkers’, ready for the validation stage. 
Using large cohorts already in this discovery phase should have a much higher 
probability to report true biomarker candidates for further investigation. We call our 
concept ‘Plasma Proteome Profiling’ and believe that it has the potential to transform 
the discovery of new disease indicators.  
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A basis of Plasma Proteome Profiling is that we aim for the lowest possible variation in 
our workflow, so as to identify even small fold changes between different study 
conditions. For this purpose, our group developed and combined several concepts and 
technological breakthroughs for the highly reproducible quantification of as many 
proteins in as many samples as possible. The major challenge of Plasma Proteomic 
Profiling lies in reaching an adequate depth of proteome coverage. As detailed below, 
we started with only a few hundred proteins but have now broken through the 1,000 
protein barrier in single-run, triplicate analyses.  
In our first publication, we described our concept by phenotyping a small cohort (Geyer 
et al., 2016a). We demonstrate that undepleted plasma from a single finger prick (5 µL 
of blood) provides ample material for Plasma Proteome Profiling. I also developed 
‘quality marker panels’ that allow the assessment of any cohort as well as individual 
samples. Subsequently, I demonstrated the broad applicability of Plasma Proteome 
Profiling by analyzing the largest number of plasma samples so far. The investigated 
study was concerned with the effects of weight loss but also provided us a treasure-
trove of new knowledge about the plasma proteome in general (Geyer et al., 2016b). 
Recently, we implemented novel approaches such as deep peptide libraries and BoxCar 
scans (patterned fill scans with high dynamic range), which resulted in unprecedented 
proteomic depth of undepleted plasma in a bariatric surgery study (Albrechtsen et al., 
2017; Kulak et al., 2017; Meier et al., 2017). In total, the bariatric surgery study quantified 
1,438 proteins in a cohort of 47 individuals, with signal intensities ranging across seven 
orders of magnitude. Our throughput is now reasonable for medium sized studies and 
results are quantitatively accurate with around 1,000 plasma proteins per sample.  
To illustrate the potential of such a proteome depth, I matched this dataset with a list of 
169 approved biomarkers with known concentrations. This revealed a highly unequal 
distribution of biomarkers across the abundance range: 21% of the proteins within the 
300 most abundant proteins were biomarkers and only 4% of the next 1,100 proteins 
(Figure 13 A). As there should be no physiological reason that biomarkers must be of 
high abundance, this observation raises the hope that there may be many yet 
undiscovered biomarkers that are accessible to our technology.  
Repeated application of Plasma Proteomics Profiling in many projects and cohorts will 
generate an extensive amount of information that can be used to construct a universal 
knowledge base of the plasma proteome. In a new departure for biomarker research, 
such a knowledge could be data-mined to reveal connections between proteins, to 
evaluate the value of a biomarker candidate and even to phenotype humans. Apart from 
the required throughput, one bottleneck of this concept is the availability of high quality, 
4. Discussion 
 
122 
large-scale studies. In general, it is already difficult to obtain access to one cohort for 
one disease. Finding a second or third cohort with a suitable design is possible, but in 
our experience requires time and effort and also involves reconciliation of the interests 
of the different partners and stakeholders.  
 
 
Figure 13: Biomarker coverage and potential for biomarker discovery of MS-based proteomics. (A) 
The average MS-intensities of nearly 1,500 proteins, which were quantified in one of our Plasma Proteome 
Profiling projects. Biomarkers (red dots) were annotated using information from our collaboration partners 
at the  Institute of Laboratory Medicine of the Ludwig-Maximilians-University and a list from (Anderson, 
2010). The percentage of biomarkers in the indicated abundance rank is provided. (B) Pie chart of the 
percentage of biomarkers in different abundance regions. The data for the Top 300 and Top 1,438 proteins 
were generated from the above mentioned dataset and the percentage of biomarkers in the Top 5,300 
proteins was determined using the data from (Keshishian et al., 2015). 
 
Of all biomarkers, 37% are within the first 300 proteins, 25% in the next 1,100 and only 
22% in the following 4,100 proteins (Figure 13 B). A total of 16% of all approved 
biomarkers were not within the 5,300 plasma proteins reported by proteomics, 
presumably because they are only increased in specific diseases or because they are 
exceedingly low abundant.  
In the future, we aim to further develop our workflow to reach greater proteomic depth 
and even higher throughput. For instance, we can now target eluting peptides in real 
time and at a large scale, an ability that is further helped by applying BoxCar windows. 
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In a plasma proteome of 2,000 proteins, targeting of three peptides for each protein 
would result in having to track 6,000 peptides. This appears to be within the 
technological possibilities of our instruments and software, especially when fractionation 
is employed. A main advantage of this strategy would be the guaranteed acquisition of 
MS2 spectra for multiple peptides per proteins, allowing very high confidence in protein 
identification. ‘Global targeting’ could also be useful to individually adjust ion fill times 
and optimized collision energies on a peptide by peptide basis. Several additional 
strategies – for instance the combination of targeting from BoxCar windows of depleted 
and fractionated plasma – could result in even deeper libraries and more targetable 
peptides.  
We are also considering to use isobaric mass tagging. Multiplexing could increase our 
throughput dramatically in single run measurements or alternatively enable fractionation 
while maintaining high throughput. Currently, we measure triplicates to ensure high 
accuracy. In a multiplexing approach, samples are directly compared to each other in 
the same spectrum, potentially obviating the need for these technical replicates. The 
throughput would be increased by the product of the multiplexing factor and this factor 
of three, resulting in up to 18-fold to 30-fold higher capacity (6-plex and 10-plex, 
respectively). With separation into six fractions, the increase would still be 3-fold to 5-
fold, with the advantage of much greater proteome depth.  
Moreover, we plan to implement a novel, highly robust and reproducible 
chromatographic set up. This builds on a rapid elution concept (Falkenby et al., 2014), 
extended to the formation of pre-formed gradients that already contain the sample. This 
system has very short overhead times as loading and equilibration are done in parallel 
and therefore has the potential to increase throughput, especially in short LC-runs. The 
increased utilization rate of our MS instruments would make it attractive to revert to very 
short gradients with injection-to-injection times of around 30 min. With fractionation, it 
may become possible to reach a depth of 1,500 plasma proteins by using the 
combination of the above mentioned developments: separation into 6 fractions and 6-
plex labeling would then result in a throughput of up to 50 plasma proteomes per day 
and instrument (Figure 14). This combination of throughput and depth would surely 
provide the basis to elevate plasma proteomics to the next level. 
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Figure 14: Potential future technological developments in Plasma Proteome Profiling. Throughput 
and depth of coverage would benefit from fractionation into an optimum of 6 fractions and further 6-plex 
multiplexing and incorporation of a novel LC concept. This would be one possible path to reach an area 
where effective biomarker discovery is possible (shaded in blue). 
 
This PhD thesis has paved the way for high throughput screening of clinical cohorts and 
already delivered the first large-scale proof-of-principle studies. The next step will be to 
implement the above mentioned technologies, which should make it possible to tackle 
clinical studies of many disease in high throughput. For this purpose, we have already 
established contacts to clinicians and researchers to create a pipeline of existing studies 
that can be analyzed. One of our aims is to measure the first population-based cohorts 
by plasma proteomics in search of predictive biomarkers and biomarker panels. In the 
past, such studies could only be assessed for the levels of candidate proteins, but 
nevertheless have delivered established risk marker like the C-reactive protein (CRP) 
or low density lipoprotein particle (LDL) (Ridker et al., 2002).  
Application of MS-based proteomics directly to patients in the clinic would be the next 
step for Plasma Proteome Profiling. In this regard, our plan is to initially use SILAC-
PrESTs for already established biomarkers for absolute and highly accurate 
quantification. SILAC-PrESTs can be easily incorporated in our workflow. It is even 
possible to store them on the StageTip matrix together with the digestion buffer. In a 
clinical setting, the plasma would be added and the mixture would be automatically 
processed to peptides.  
For some clinical tests time plays a crucial role, which means that samples have to be 
processed in a sequential manner rather than in batches like in our 96 sample set up. 
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For this purpose, processing workflows such as those implemented in clinical high 
throughput platforms can be adapted. In some case, samples have to be analyzed faster 
than the 3h from sample to result that we have already demonstrated (Geyer et al., 
2016a). However, even clinical assays that have to be performed in minutes, such as 
the troponin tests for myocardial infarction, are not necessarily beyond the reach of 
proteomics. Immobilized trypsin can in principle digest proteins in a flow-through system 
and the novel HPLC system alluded to above could start measurements within a few 
minutes. It is clear that many developments would be necessary to implement 
proteomics in the clinical laboratory and a complete automatized pipeline would call for 
partners in industry.  
A principal advantage of MS-based proteomics over immunoassays is its ability to 
multiplex without interference. Immunoassays are constrained by cross-reactions of the 
antibodies and their interactions with other molecules, which can result in compromised 
accuracy and severely limits the number of simultaneous assays (Ellington et al., 2010). 
In contrast, MS-based proteomics allows the simultaneous analysis of as many proteins 
as desired for biomarker panels. Such panels could be designed to cover markers for 
differential diagnosis of diseases with similar symptoms as well as quality marker panels 
to exclude samples of poor quality.  
Even proteins that are not included in the SILAC-PrEST mixtures are not entirely lost 
because they can still be quantified in a label-free manner at lower accuracy. Such data 
could be blinded and stored together with anonymized patient metadata. Alternatively, 
if participants have given consent, it would be possible to use a wide range of patient 
data, including treatment history amongst others, via patient unique IDs. This is already 
the practice in Denmark where every person has a Civil Personal Registration (CPR) 
number, which is linked to all their data. This allows ‘big data’ mining for cross-
correlations, subclassifications of diseases and identification of potential predictive 
external factors like drug prescription or life style factors. Such data mining approaches 
from available clinical data have already been investigated in other contexts (Beck et 
al., 2016; Ellesoe et al., 2016; Jensen et al., 2014). 
A seemingly minor feature of our Plasma Proteome Profiling approach is that it only uses 
microliter amounts from fingerpricks instead of the large volumes of venous blood that 
are routinely taken. We already demonstrated that fingerpricks result in highly 
reproducible quantification and we have identified the few proteins prone to variation 
due to the finger pricking process (Geyer et al., 2016a). Fingerpicks can be obtained 
with much higher frequency from adults and are even appropriate for infants. Even dried 
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blood spots could be analyzed. This would dramatically expand the application of 
Plasma Proteome Profiling in health and disease.  
In summary, this PhD thesis has developed the concept and practice of Plasma 
Proteome Profiling as a fundamentally new approach in biomarker research and medical 
diagnostics, leading to a system-wide phenotyping of humans in health and disease.  
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